Top 10 Peptide Synthesis Companies

Published: May 2024


The future success of the peptide synthesis market is driven by strategic initiaives by peptide API contract manufacturers. We analyzed over 75 companies that are engaged in the contract manufacturing of peptide APIs. In this article, discover top 10 peptide synthesis companies and their service portfolio related to peptide synthesis.


Peptides are the signaling molecules that bind to specific receptors present on the cell surface and trigger intracellular effects. These molecules are capable of regulating the physiological functions and metabolic synthesis of various components, as well as providing nutrition to the body. It is worth noting that peptides are polymers of amino acids, which are linked through peptide bonds formed between the carboxyl group and the amine group. When these peptides are linked together, they form a polypeptide; molecules containing two to ten amino acids are known as oligopeptides, while those having more than ten amino acids are called polypeptides. Further, subsequent linking of polypeptides leads to the formation of proteins.

Peptide therapeutics have become a prominent segment in the overall biopharmaceutical domain. It is worth highlighting that over 80 peptide therapeutics have been approved till date, across the globe, while more than 300 molecules are being evaluated in clinical trials across different phases of development. The increasing popularity and demand for peptide drugs can be attributed to the fact that these therapeutic candidates have demonstrated capability to treat a myriad of disorders, including various cardiovascular disorders, metabolic disorders and oncological disorders. Driven by such high demand, specifically for GLP-1 drugs, and technological advancements, the peptide synthesis market is poised to grow in the long-run.

Roots Analysis has conducted an exhaustive study on peptide synthesis market featuring the current market landscape and future opportunity for the companies offering contract manufacturing services for peptide synthesis, over a span of 12 years.

Table of Contents

Below, we have listed (in alphabetical order), the top 10 peptide synthesis companies.

  1. AmbioPharm
  2. Auspep
  3. Bachem
  4. BCN Peptides
  5. Chinese Peptide
  6. CordenPharma
  7. CPC Scientific
  8. CSBio
  9. Peptide Institute
  10. PolyPeptide

Top 10 Peptide Synthesis Companies

Interested in exploring all 75+ peptide synthesis companies, including GLP manufacturing, and their recent initiatives?

Discover Below the Details on 5 of the top 10 Peptide Synthesis Companies

Let us deep dive to understand the activity of the 5 of the top 10 peptide synthesis companies (shortlisted on the basis of service portfolio). It is essential to note that the selection of top players can differ substantially according to the defined criteria.

AmbioPharm is Setting New Benchmarks in Comprehensive cGMP Peptide Manufacturing

1. AmbioPharm

AmbioPharm is a US-based company that claims to offer cGMP manufacturing services for peptide APIs, across all scales of operation. Additionally, it is engaged in the production of generic peptide-based products at commercial scale and provides non-GMP manufacturing services for peptides for clinical research purposes. It is also worth highlighting that the company uses various chemical methods, such as solid phase synthesis, solution phase and hybrid phase synthesis to carry out manufacturing operations.

AmbioPharm: Company Details

Particulars Specifications
Company Logo AmbioPharm, Top Dermal Filler Companies
Year of Establisment   2005
Number of Employees  501-1,000
Headquarter AmbioPharm, Headquarter
Key Executives 
  • Juncai (Chris) Bai (Executive Director, Founder and Chairman of the Board)
  • Brian Gregg (Chief Executive Officer) 
  • Stephen John Kiel (Chief Financial Officer)
  • Mike Pennington (Chief Scientific Officer)
  • Brant Zell (Senior Vice President, Quality)
  • Guoqing Zhang (Vice President, Manufacturing and Process Development)
  • Mukesh Patel (Vice President, Manufacturing)
  • Mark DaFonseca (Executive Vice President)
  • Kathleen Noack (Vice President, Sales)
  • Peter Hutchings (Vice President, Sales)
  • Gary T.K. Hu (Senior Vice President of Sales, Asia)


AmbioPharm: Overview of Peptide Manufacturing Capabilities

S.No. Key Parameters US-based Facility China-based Facility
1 Number of Manufacturing Facilities 1 1
2 Location South Carolina Shanghai
3 GMP Compliant Yes Yes
4 Scale of Operation Preclinical, clinical and commercial Preclinical, clinical and commercial
5 Area Dedicated for Peptide Manufacturing 82,566 sq. ft. 380,550 sq. ft.
6 Peptide Synthesis Method Used Solid phase and solution phase synthesis Solid phase and solution phase synthesis
7 Purification Technique Used HPLC HPLC
8 Number of Employees >200 >375
9 Accreditations USFDA USFDA


Recent Development: In September 2023, AmbioPharm entered into a partnership with CombiGene to develop COZY01 peptide for Zynero and Combigene’s combined peptide-based pain project.

Further details on recent initiatives taken by AmbioPharm as well as other peptide synthesis companies have been provided in detail in the report.

Auspep is Australian Peptide Manufacturer with GMP Certification, Offering Custom Peptide Synthesis and Peptide Modification Services

2. Auspep

Auspep is an Australian company that claims to be engaged in the manufacturing of peptide APIs, at small and large scale of operation. In addition, it provides peptide modification services, such as the incorporation of unnatural amino acids, complex and custom peptides, using a range of innovative technologies. Furthermore, the company claims to be the peptide manufacturer in Australia to have received GMP certification.

Auspep: Company Details

Particulars Specifications
Company Logo Auspep, Top Dermal Filler Companies
Year of Establisment   1987
Number of Employees  11-50
Headquarter Auspep, Headquarter
Key Executives 
  • John Andreas Nissen (Director)
  • Christopher Chandler (Managing Director)
  • Klaas Pool (Director)

 

Auspep: Overview of Peptide Manufacturing Capabilities

S.No. Key Parameters Australia-based Facility
1 Number of Manufacturing Facilities 1
2 Location Melbourne
3 GMP Compliant Yes
4 Scale of Operation Preclinical, clinical and commercial
5 Peptide Synthesis Methos Used Solid phase and Liquid phase synthesis
6 Purification Technique Used HPLC
7 Accreditations USFDA and EMA


Recent Development: In February 2023, Auspep entered into a partnership with Argenica Therapeutics for a preclinical program that is designed to assess the efficacy of ARG-007 for the treatment of mild to moderate traumatic brain injury.

Further details on recent initiatives taken by Auspep as well as other peptide synthesis companies have been provided in detail in the report.

Bachem is Amongst the Leading Peptide Synthesis Companies with Innovative Molecular Hiving Technology

3. Bachem

Bachem, a Switzerland-based company with an experience of 50 years in this domain, claims to be engaged in the development of a wide range of peptides. Additionally, the firm states to provide customized peptides to cater to the needs of researchers based across the globe. As per the firm’s website, it is engaged in the manufacturing of cosmetic peptides using the Molecular Hiving technology, licensed from JITSUBO.

Bachem: Company Details

Particulars Specifications
Company Logo Bachem, Top Dermal Filler Companies
Year of Establisment   1971
Number of Employees  1,001-5,000
Headquarter Bachem, Headquarter
Key Executives 
  • Thomas Meier (Chief Executive Officer and Chief Operations Officer)
  • Alain Schaffter (Chief Financial Officer)
  • Günther Loidl (Chief Technology Officer)
  • Torsten Wöhr (Chief Commercial Officer)
  • Ezzeddin Ben Rayana (Vice President, QA, QC and RA)
  • Stephan Eissler (Vice President, Peptide Manufacturing Upstream)

 

Bachem: Overview of Peptide Manufacturing Capabilities

S.No. Key Parameters US-based Facility Switzerlan-based Facility
1 Number of Manufacturing Facilities 2 2
2 Location Carolina Bubendrof and Vionnaz
3 GMP Compliant Yes Yes
4 Scale of Operation Preclinical, clinical and commercial Preclinical, clinical and commercial
5 Peptide Synthesis Method Used Solid and solution phase synthesis Solid and solution phase synthesis
6 Purification Technique Used HPLC, ion-exchange and size-exclusion
chromatography
HPLC, ion-exchange and size-exclusion
chromatography
7 Manufacturing Capacity Solution phase: 8,000 L
Solid phase: 150 L
Solution phase: 8,000 L
Solid phase: 150 L
8 Accreditations USFDA USFDA and Swissmedic


Recent Development: In March 2023, Bachem entered into a long-term partnership with an undisclosed partner for providing large volumes of peptides, which is expected to be worth nearly CHF 500 million, for the period 2027- 2031. Further, in the same month, company raised CHF 108.1 million through secondary offering, which the company plans to utilize for capacity expansion of its numerous production facilities.

Further details on recent initiatives taken by Bachem as well as other peptide synthesis companies have been provided in detail in the report.

CordenPharma Expands Early Clinical Peptide Manufacturing to Launch IND-Targeted Peptide API to Injectable Drug Product

4. CordenPharma

CordenPharma is a German CDMO that claims to be engaged in providing a wide range of services for APIs, drug products and pharma packaging. As per the firm’s website, it currently supports the development of more than 50 cGMP projects, involving both New Chemical Entities (NCEs) as well as peptide generics. Additionally, it states to have various proprietary technology platforms for the development of peptides, lipids and carbohydrates, injectables, small molecules and antibiotics. It is worth highlighting that in May 2022, CordenPharma was acquired by Astorg.

CordenPharma: Company Details

Particulars Specifications
Company Logo CordenPharma, Top Dermal Filler Companies
Year of Establisment   2006
Number of Employees  1,001-5,000
Headquarter CordenPharma, Headquarter
Key Executives 
  • Michael Quirmbach (Chief Executive Officer)
  • Gary Hughes (Chief Financial Officer)
  • Lee Newton (Chief Operating Officer)
  • William Cashin (Chief Quality and Comliance Officer)
  • Stéphane Varray (Director, Global Peptides Platform)

 

CordenPharma: Overview of Peptide Manufacturing Capabilities

S.No. Key Parameters US-based Facility Belgium-based Facility Germany-based Facility
1 Number of Manufacturing Facilities 1 1 1
2 Location Colorado Brussels Frankfurt
3 GMP Compliant Yes Yes Yes
4 Scale of Operation Commercial Preclinical, clinical and commercial Preclinical, clinical and commercial
5 Peptide Synthesis Method Used Liquid phase synthesis Liquid phase, solid phase and hybrid synthesis Liquid phase and solid phase
6 Purification Technique Used Ion-exchange, size-exclusion chromatography HPLC, UPLC and ion-exchange chromatography HPLC
7 Manufacturing Capacity 10,000 L Large scale-up to 100 kg
Medium scale-up to 10 kg
Small scale-up to 2 kg
Milligrams to multi 100 grams
8 Accreditations USFDA USFDA and EMA -


Recent Development: In April 2024, CordenPharma announed the commissioning of new 1,000 m2 GMP capacities at Frankfurt to manufacture early clinical phase peptide APIs.

Further details on recent initiatives taken by CordenPharma as well as other peptide synthesis companies have been provided in detail in the report.

Peptide Institute is Pioneering Peptide Manufacturing by Offering Comprehensive Services from Research and Development to Commercialization

5. Peptide Institute

Peptide Institute was formed as a spin off from the Osaka University Institute for Protein Research Foundation, in 1977. The company claims to provide a wide range of services for peptide drug substances, spanning from research and development to commercialization.

Peptide Institute: Company Details

Particulars Specifications
Company Logo Peptide Institute, Top Dermal Filler Companies
Year of Establisment   1977
Headquarter Peptide Institute, Headquarter
Key Executives 
  • Masahiko Tsunemi (President)
  • Taku Yoshiya (Executive Vice President)
  • Tatsuya Inui (Director)

 

Peptide Institute: Overview of Peptide Manufacturing Capabilities

S.No. Key Parameters Japan-based Facility
1 Number of Manufacturing Facilities 1
2 Location Osaka
3 GMP Compliant Yes
4 Scale of Operation Preclinical, clinical and commercial
5 Peptide Synthesis Methos Used Solid phase and solution phase synthesis
6 Purification Technique Used HPLC and ion-exchange chromatography
7 Manufacturing Capacity 10 mg to Kg
8 Accreditations ICH


Recent Development: In order to help support the development of therapeutics and vaccines against the novel coronavirus (COVID-19), the company entered into a product development agreement with AnGes in April 2020.

Further details on recent initiatives taken by Peptide Institute as well as other peptide synthesis companies have been provided in detail in the report.

What About the Peptide Synthesis Companies Around the World?

The above presentation features details on 5 of the top 10 peptide synthesis companies selected from a pool of more than 75 companies that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.

About Author

Ronit_Sharma

Ronit Sharma is an accomplished business research and competitive intelligence professional with about seven years of experience in the pharmaceutical and healthcare industry. As a team leader at Roots Analysis, he has authored numerous multidisciplinary market research reports, and led the efforts on several bespoken consulting assignments, providing valuable insights into the latest innovations in healthcare and the digital transformation of the pharmaceutical industry. Ronit's exceptional analytical skills and strategic thinking in the field contribute to the firm's intellectual capital, empowering clients to make informed decisions in the dynamic pharmaceutical landscape. With a passion for staying at the forefront of industry advancements, Ronit specializes in identifying emerging opportunities for various stakeholders, leveraging his deep understanding of market trends and technological developments. He is committed to fostering an environment of excellence, creativity, and innovation within his team, encouraging collaboration and empowering team members to bring their best ideas to the table.

Ronit holds a B. Tech degree in Biotechnology from Lovely Professional University and his research and thought leadership can be found in his professional blog and social media profiles, where he shares the latest insights and engages in meaningful discussions with industry peers. To ensure the highest ethical standards, Ronit openly declares no conflicts of interest in his work, ensuring unbiased and trustworthy contributions. His insights undergo rigorous editorial and peer-review processes, establishing his credibility as a thought leader within the pharmaceutical and healthcare domain. Ronit's exceptional analytical and strategic thinking skills, coupled with his commitment to excellence, make him a valuable asset to any organization in the pharmaceutical and healthcare industry.

Email: ronit.sharma@rootsanalysis.com
LinkedIn: https://www.linkedin.com/in/ron001/

Sources

  1. https://www.ambiopharm.com/news-press/combigene-selects-ambiopharm-as-peptide-cdmo-partner-for-their-cozy01-pain-project
  2. https://www.perroninstitute.org/argenica-awarded-1-2m-grant-for-traumatic-brain-injury-project/
  3. https://www.bachem.com/news/bachem-signs-long-term-cooperation-agreement-for-the-development-and-supply-of-peptides/
  4. https://www.bcnpeptides.com/successful-regulatory-inspections-and-gmp-renewal/
  5. https://www.chinesepeptideco.com/exhibition-review-chinese-peptide-company-attended-the-3rd-china-polypeptide-industry-conference.html
  6. https://cordenpharma.com/articles/integrated-peptide-injectable-manufacturing-targeted-for-first-in-human-clinical-trials/
  7. https://cpcscientific.com/cpc-scientific-announces-new-california-peptide-manufacturing-facility/
  8. https://www.csbio.com/blog/nervgen.html
  9. https://pj.jiho.jp/article/241915
  10. https://www.polypeptide.com/news/polypeptide-signs-scientific-collaboration-agreement/

MEDIA CITATIONS

  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry